The PROSIT-BIO Cohort-Reference-Cited by-同舟云学术

The PROSIT-BIO Cohort

Published:2017-02 Issue:2 Volume:23 Page:233-243
ISSN:1078-0998
Container-title:Inflammatory Bowel Diseases
language:en
Short-container-title:Inflammatory Bowel Diseases

Author:

Fiorino Gionata,Manetti Natalia,Armuzzi Alessandro,Orlando Ambrogio,Variola Angela,Bonovas Stefanos,Bossa Fabrizio,Maconi Giovanni,DʼIncà Renata,Lionetti Paolo,Cantoro Laura,Fries Walter,Annunziata Maria L.,Costa Francesco,Terpin Maria M.,Biancone Livia,Cortelezzi Claudio C.,Amato Arnaldo,Ardizzone Sandro,Danese Silvio,Guidi Luisa,Rizzuto Giulia,Massella Arianna,Andriulli Angelo,Massari Alessandro,Lorenzon Greta,Ghione Silvia,Kohn Anna,Ventra Agostino,Annese Vito

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,Immunology and Allergy

Reference42 articles.

1. Biologic agents for IBD: practical insights

2. Impact of New Treatments on Hospitalisation, Surgery, Infection, and Mortality in IBD: a Focus Paper by the Epidemiology Committee of ECCO

3. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study

4. Economics of the Use of Biologics in the Treatment of Inflammatory Bowel Disease

5. The advent of biosimilar therapies in rheumatology—“O Brave New World”

Cited by 122 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical experience of using biosimilars in Crohn’s disease and their effectiveness;Expert Opinion on Biological Therapy;2024-09-13

2. Anti-TNFα in inflammatory bowel disease: from originators to biosimilars;Frontiers in Pharmacology;2024-07-24

3. Systematic review: effectiveness and safety of switching between originator infliximab and biosimilar infliximab in patients with inflammatory bowel disease;Expert Opinion on Biological Therapy;2024-07-02

4. Clinical use of biologics for Crohn’s disease in adults: lessons learned from real-world studies;Expert Opinion on Biological Therapy;2024-02-23

5. Challenges in Therapeutic Drug Monitoring: Optimizing Biological Treatments in Patients With Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases;Therapeutic Drug Monitoring;2023-04-03